NCT06434077View on ClinicalTrials.gov

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

September 20, 2026

Study Completion Date

December 20, 2026

Conditions
Breast Cancer
Interventions
BIOLOGICAL

GcMAF injections (100 ng)

The GcMAF 100 ng (Gc protein macrophage-activating factor) will be injected subcutaneously.

OTHER

placebo

the placebo solution will be injected subcutaneously 100 ng.

Trial Locations (1)

630090

Center of New Medical Technologies, Novosibirsk

Sponsors
All Listed Sponsors
collaborator

Center of New Medical Technologies

OTHER

lead

S.LAB (SOLOWAYS)

OTHER